¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"intraepithelial neoplasia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • intraepithelial neoplasia
    »óÇdz»Á¾¾ç
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cervical intraepithelial neoplasia
    Àڱøñ»óÇdz»Á¾¾ç, ÀڱðæºÎ»óÇdz»Á¾¾ç
  • endometrial intraepithelial neoplasia
    Àڱ󻸷»óÇdz»Á¾¾ç
  • prostatic intraepithelial neoplasia
    Àü¸³»ù»óÇdz»Á¾¾ç, Àü¸³¼±»óÇdz»Á¾¾ç
  • hereditary benign intraepithelial dyskeratosis
    À¯Àü¾ç¼º»óÇdz»ÀÌ»ó°¢È­Áõ
  • high-grade squamous intraepithelial lesion
    °íµî±ÞÆíÆò»óÇdz»º´ÅÍ
  • intraepithelial carcinoma
    »óÇdz»¾Ï(Á¾)
  • intraepithelial gland
    »óÇǼӻù, »óÇdz»¼±
  • squamous intraepithelial lesion
    ÆíÆò»óÇdz»º´ÅÍ
  • gestational trophoblastic neoplasia
    ÀÓ½ÅÀ¶¸ðÁ¾¾ç
  • multiple endocrine neoplasia
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • neoplasia
    ½Å»ý¹°, Á¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • intraepithelial neoplasia
    »óÇdz»Á¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cervical intraepithelial neoplasia
    Àڱøñ»óÇdz»Á¾¾ç
  • high grade squamous intraepithelial lesion
    °íµî±ÞÆíÆò»óÇdz»º´ÅÍ
  • neoplasia
    ½Å»ý¹°, Á¾¾ç
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • intraepithelial neoplasia
    »óÇdz»Á¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endometrial intraepithelial neoplasia
    Àڱ󻸷»óÇdz»Á¾¾ç
  • gestational trophoblastic neoplasia
    ÀÓ½ÅÀ¶¸ðÁ¾¾ç
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • neoplasia
    ½Å»ý¹°, Á¾¾ç
  • intraepithelial carcinoma
    »óÇdz»¾ÏÁ¾, Ç¥ÇǼӾÏÁ¾
  • hereditary benign intraepithelial dyskeratosis
    À¯Àü¾ç¼º»óÇdz»ÀÌ»ó°¢È­Áõ
  • intraepithelial gland
    »óÇǼӻù
  • squamous intraepithelial lesion
    ÆíÆò»óÇdz»º´ÅÍ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • VAIN; vaginal intraepithelial neoplasia
    Áú »óÇdz»Á¾¾ç
  • VIN; vulvar intraepithelial neoplasia
    ¿ÜÀ½ºÎ »óÇdz»Á¾¾ç
  • prostatic intraepithelial neoplasia
    Àü¸³¼±»óÇdz»Á¾¾ç(îñí¡àÍß¾ù«Ò®ðþåË)
  • gestational trophoblastic neoplasia
    Àӽżº À¶¸ð¼º Á¾¾ç
  • hereditary benign intraepithelial dyskeratosis
    À¯Àü¼º ¾ç¼º »óÇdz» ÀÌ»ó°¢È­Áõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • intraepithelial neoplasia
    »óÇdz» Á¾¾ç(¡­ ðþåË)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endometrial intraepithelial neoplasia
    Àڱ󻸷 »óÇdz»Á¾¾ç
  • prostatic intraepithelial neoplasia
    Àü¸³¼±»óÇdz»Á¾¾ç(îñí¡àÍß¾ù«Ò®ðþåË)
  • hereditary benign intraepithelial dyskeratosis
    À¯Àü¼º ¾ç¼º »óÇdz» ÀÌ»ó°¢È­Áõ
  • intraepithelial carcinoma = IEC
    »óÇdz»¾ÏÁ¾(ß¾ù«Ò®äßðþ)
  • intraepithelial gland
    »óÇdz»¼±(¡­àÊ).
  • intraepithelial gland
    »óÇǼӻù
  • intraepithelial plexus of cornea
  • squamous intraepithelial lesions
    ÆíÆò¼¼Æ÷ »óÇdz»º´º¯
  • gestational trophoblastic neoplasia
    Àӽżº À¶¸ð¼º Á¾¾ç
  • multiple endocrine neoplasia
    ´Ù¹ß¼º ³»ºÐºñ ½Å»ý¹°
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ¼±½Å»ý¹°(ãæßæÚª)
  • multiple endocrine neoplasia syndrome
    ´Ù¹ß¼º ³»ºÐºñ¼±Á¾Áõ
  • multiple endocrine neoplasia(MEN)
  • neoplasia
    ½Å»ý¹°
  • neoplasia
    ½Å»ý¹°
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Intraepithelial gland
    »óÇǼӻù
    [¿¾ ¿ë¾î] »óÇdz»¼±
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neoplasia
    ½Å»ý¹°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CIN Cervical Intraepithelial Neoplasia
CIN central inhibition; cervical intraepithelial neoplasia; chronic interstitial nephritis
CIN1, CIN I cervical intraepithelial neoplasia, grade 1 (mild dysplasia)
CIN 2, CIN II cervical intraepithelial neoplasia, grade 2 (moderate-severe)
CIN 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AIN Anal intraepithelial neoplasia
CIN 3 Cervical Intraepithelial Neoplasia grade 3
CIN III Cervical intraepithelial neoplasia grade III
HGPIN High grade prostatic intraepithelial neoplasia
PIN Prostate intraepithelial neoplasia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • intraepithelial bullae
    »óÇdz» ¼öÆ÷
  • intraepithelial dyskeratosis
    »óÇdz» À̰¢È­Áõ
  • middle ear neoplasia
    ÁßÀÌÀÇ ½Å»ý¹°
    ÁßÀÌ¿¡ ÀÏÂ÷ÀûÀ¸·Î ¹ß»ýÇÏ´Â Á¾¾çÀº µå¹°´Ù. »ç±¸Á¾¾ç
  • multiple endocrine neoplasia
    ´Ù¹ß¼º ³»ºÐºñ Á¾¾ç
  • neoplasia
    ½Å»ý¹°, ½ÅÇü¼º, ÀÌ»ó Áõ½Ä, Á¾¾ç Çü¼º
    ½Å»ý¹°ÀÇ Çü¼º, Áï Á¤»ó ¼¼Æ÷ÀÇ Áõ½ÄÀ» ÀÏÀ¸Å°Áö ¾Ê°Å³ª Áõ½ÄÀ» Á¤Áö½ÃŰ´Â »óÅ ÇÏ¿¡¼­ ÁøÇ༺ÀÎ ¼¼Æ÷ Áõ½ÄÀÌ ÀϾ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cervical intraepithelial neoplasia A term which describes precancerous changes to the epithelial cells lining the cervix. The diagnosis is made from the microscopic examination of a PAP smear acquired tissue specimen. Less than 5% of all PAP smears will show cervical dysplasia. The peak incidence is in women 25 to 35 years of age. Risk factors include multiple sexual partners, early onset of sexual activity (less than 18), early childbearing (less than 16) and past medical history of a sexually transmitted disease (for example genital warts, genital herpes, HIV infection). Treatment is based on the degree of dysplasia present, as judged by a pathologist. Treatments include cryotherapy and conisation.
Origin: Gr. Plassein = to form
(27 Sep 1997)
prostatic intraepithelial neoplasia A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.
(12 Dec 1998)
hereditary benign intraepithelial dyskeratosis An autosomal dominant condition consisting of white spongy lesions of the buccal mucosa, floor of the mouth, ventral lateral tongue, gingiva and palate. Transient gelatinous plaques form over the cornea, which may produce temporary blindness, hereditary benign intraepithelial dyskeratosis.
Synonym: hereditary benign intraepithelial dyskeratosis.
(05 Mar 2000)
squamous intraepithelial lesion A general term for the abnormal growth of squamous cells on the surface of the cervix. The changes in the cells are described as low grade or high grade, depending on how much of the cervix is affected and how abnormal the cells are. Also called sil.
(12 Dec 1998)
intraepithelial Within the layer of cells that forms the surface or lining of an organ.
(12 Dec 1998)
intraepithelial carcinoma Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts.
(16 Dec 1997)
intraepithelial dyskeratosis An autosomal dominant condition consisting of white spongy lesions of the buccal mucosa, floor of the mouth, ventral lateral tongue, gingiva and palate. Transient gelatinous plaques form over the cornea, which may produce temporary blindness, hereditary benign intraepithelial dyskeratosis.
Synonym: hereditary benign intraepithelial dyskeratosis.
(05 Mar 2000)
intraepithelial glands Accumulations of glandular cells that lie within an epithelium, as those of the urethra.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
intraepithelial neoplasia Abnormal cell growth that is found within epithelial cells but has not yet spread to neighboring, underlying, or distant tissues. Intraepithelial neoplasia is thought to be an early marker of some cancers, e.g., cancers
Ãâó:
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á